Related Articles

• Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
• Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer
• Conversion to monotherapy with luteinizing‑hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression‑free survival in patients with metastatic prostate cancer: A propensity score matching analysis
• Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report
• PSA response following the ‘steroid switch’ in patients with castration‑resistant prostate cancer treated with abiraterone: A case report